Good idea, but alas I think it will never happen. There's a good case for a big chunk of listed biotech wannabes being forced private, delisted or merged, but ego, vested interests and money-go-round gravy trains always seem to get in the way.
AT1 and LDX have good ideas, but turning those ideas into sustainable businesses is an elusive goal. Two wrongs won't neccessarily make a right.
Ann: Appointment of Independent Non-Executive Director, page-4
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AT1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.34M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 497908 | 2.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.5¢ | 67200 | 3 |
View Market Depth
| Last trade - 16.12pm 02/08/2024 (20 minute delay) ? |
| AT1 (ASX) Chart |
Day chart unavailable